Ruth Roberts on SOT Ballot

ApconiX is happy to announce that Ruth Roberts is on the SOT ballot for the position of Vice President-Elect.  As Secretary to SOT, Ruth was the first non-US based Council member and now hopes to be the first non-US based President! ‘It’s a great honour to be asked to stand for election to lead the [...]

By |2019-01-09T15:49:13+00:00January 9th, 2019|Events|Comments Off on Ruth Roberts on SOT Ballot

Highlight Article for Experimental Biology and Medicine

“Drug discovery and development: Biomarkers of neurotoxicity and neurodegeneration”, co-authored by Abigail L Walker, Syed Z Imam and  Ruth A Roberts, has been selected as a highlight article for Experimental Biology and Medicine’s 243:13 issue. As a result of this designation it will be open access for 90 days. Click here to access Abstract The [...]

By |2018-12-06T13:53:13+00:00December 7th, 2018|Publications|Comments Off on Highlight Article for Experimental Biology and Medicine

Choosing the right non-clinical CRO

Non-clinical contract research organisations (CROs) are an integral part of modern drug development. For any novel agent, delivery of GLP toxicity data to support clinical trials is a crucial step that requires a professional organisation with dedicated management, infrastructure and a broad array of technical and scientific skills. In selecting a CRO, the sponsor typically [...]

By |2018-09-12T14:07:14+00:00September 19th, 2018|Toxicology, Press|Comments Off on Choosing the right non-clinical CRO

Accelerating Cancer Drug Development

Accelerating Cancer Drug Development -From target to patients, BioNow will be hosting this event at Alderley Park on the 27th of February 2018. Focusing upon the strengths in the discovery, development and manufacture of cancer medicines in the North of England through to commercialisation (patients), this event will highlight industry, academic and clinical strengths whilst [...]

By |2018-07-11T11:58:57+00:00February 27th, 2018|Events|Comments Off on Accelerating Cancer Drug Development

Collaboration and Competition: Ethics in Toxicology

Two of the biggest ethical challenges in pharmaceutical toxicology are the use of animals in testing and the high safety-related attrition rates in new drug development.  Yet very little is invested in these two fields compared with investment in new efficacy models, new disease targets and new technologies.  How can this be addressed?  In this [...]

By |2018-05-30T16:00:00+00:00February 9th, 2018|Toxicology, Publications|Comments Off on Collaboration and Competition: Ethics in Toxicology

New Drug Discovery Alliance to Tackle High Rate of Failure

Two prominent preclinical safety companies have launched a unique European alliance to address the high safety-related failure rate in drug development. This alliance will provide both high-throughput ion channel screening, advanced cardiovascular safety testing models and experienced project scientists in one collaborative team. This enables both large and small pharmaceutical companies to make the right [...]

By |2018-06-27T16:34:31+00:00September 20th, 2017|Press|Comments Off on New Drug Discovery Alliance to Tackle High Rate of Failure

APTrans signs agreement with Evgen Pharma to support the development of the lead product, SFX-01.  

In February, APTrans signed a service agreement with Evgen Pharma to provide support to their lead program, SFX-01. Evgen Pharma is a clinical stage drug development company with projects in breast cancer and subarachnoid haemorrhage. APTrans is a consortium of companies based at the BioHub at Alderley Park, formed by ApconiX, Aptus Clinical and Seda [...]

By |2018-07-11T16:56:25+00:00March 8th, 2017|Press|Comments Off on APTrans signs agreement with Evgen Pharma to support the development of the lead product, SFX-01.